INNV on Nasdaq
InnovAge Holding Corp.
In its 2026 annual report the company says: “InnovAge is the leading healthcare delivery platform by number of participants focused on providing all-inclusive, capitated care to high-cost, seniors, many of whom are dual-eligible. Our programs are designed to address two of the most pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes.”5 It is headquartered in Denver, Colorado.1 Its shares trade on Nasdaq under the symbol INNV.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Pennant Group, Inc., U S PHYSICAL THERAPY INC /NV or LifeStance Health Group, Inc., or pick any stock.
- TickerINNV on Nasdaq1
- IndustryServices-Health Services1
- HeadquartersDenver, Colorado1
- Incorporated inDE3
- Business address8950 E. Lowry Boulevard, Denver, Co 802303
- Filer categoryAccelerated filer, Smaller reporting company3
See how the biggest companies compare on our leaderboards
InnovAge is the leading healthcare delivery platform by number of participants focused on providing all-inclusive, capitated care to high-cost, seniors, many of whom are dual-eligible. Our programs are designed to address two of the most pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of our participant-centered care delivery approach is to improve the quality of care our participants receive, while keeping them in their homes for as long as safely possible and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. Through our Program of All-Inclusive Care for the Elderly (“PACE”), we fulfill a broad range of medical and ancillary services for seniors, including in-home care services (skilled, unskilled and personal care), in-center services such as primary care, physical therapy, occupational therapy…5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Capitation revenue brought in 100% of the revenue InnovAge Holding Corp. broke down this way in fiscal 2026.
Products and services by year
| Products and services | 2025 | 2026 |
|---|---|---|
| Capitation revenue | $852.4M | $988.4M |
| Other service revenue | $1.3M | $1.3M |
Business segments
PACE brought in 100% of the revenue InnovAge Holding Corp. broke down this way in fiscal 2026.
Business segments by year
| Business segments | 2025 | 2026 |
|---|---|---|
| PACE | $852.7M | $989.5M |
| Other Operating | $990.0K | $257.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Other costs100¢$988.8M
- Income tax0¢$949.0K
Out of $989.7M in revenue.2 The company lost money this year.
Where each dollar of operating cash went, fiscal 2026
- Capital spending22¢$14.3M
- Kept or used elsewhere78¢$50.4M
Out of $64.7M of cash from operations.2
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Total revenues | $989.7M | $853.7M |
| External provider costs | $449.8M | $431.2M |
| Cost of care, excluding depreciation and amortization | $312.1M | $268.9M |
| Sales and marketing | $34.4M | $28.2M |
| Corporate, general and administrative | $166.5M | $122.1M |
| Depreciation and amortization | $21.1M | $19.5M |
| Impairments and loss on assets held for sale | $3.2M | $13.6M |
| Total expenses | $987.1M | $883.5M |
| Operating Income (Loss) | $2.6M | -$29.8M |
| Interest expense, net | -$4.3M | -$4.6M |
| Loss on cost and equity method investments | $0 | -$1.4M |
| Other income, net | $1.9M | $1.7M |
| Total other expense | -$2.4M | -$4.3M |
| Income (Loss) Before Income Taxes | $266.0K | -$34.0M |
| Provision for Income Taxes | $949.0K | $1.3M |
| Net Loss | -$683.0K | -$35.3M |
| Less: net income (loss) attributable to noncontrolling interests | $1.9M | -$5.0M |
| Net Loss Attributable to InnovAge Holding Corp. | -$2.5M | -$30.3M |
| Weighted-average number of common shares outstanding - basic (in shares) | 135.7M shares | 135.4M shares |
| Weighted-average number of common shares outstanding - diluted (in shares) | 135.7M shares | 135.4M shares |
| Net loss per share - basic (in dollars per share) | -$0.02 | -$0.22 |
| Net loss per share - diluted (in dollars per share) | -$0.02 | -$0.22 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Cash and cash equivalents | $97.9M | $64.1M | |
| Short-term investments | $43.4M | $41.8M | |
| Restricted cash | $10.0K | $11.0K | |
| Accounts receivable | $42.4M | $36.4M | |
| Prepaid expenses and other | $27.3M | $24.5M | |
| Income tax receivable | $3.3M | $3.3M | |
| Assets held for sale | $0 | $6.0M | |
| Total current assets | $214.3M | $176.1M | |
| Property and equipment, net | $166.1M | $168.0M | |
| Operating lease assets | $21.4M | $26.9M | |
| Deposits and other | $10.3M | $9.9M | |
| Goodwill | $142.0M | $142.0M | $139.9M |
| Other intangible assets, net | $3.2M | $3.9M | |
| Total noncurrent assets | $343.1M | $350.7M | |
| Total assets | $557.4M | $526.9M | |
| Accounts payable and accrued expenses | $115.4M | $76.8M | |
| Reported and estimated claims | $56.9M | $59.0M | |
| Due to Medicaid and Medicare | $18.3M | $14.4M | |
| Current portion of long-term debt | $2.5M | $2.2M | |
| Current portion of finance lease obligations | $6.3M | $5.2M | |
| Current portion of operating lease obligations | $4.6M | $4.7M | |
| Liabilities held for sale | $0 | $2.5M | |
| Total current liabilities | $203.9M | $164.8M | |
| Deferred tax liability, net | $9.1M | $8.8M | |
| Finance lease obligations | $8.3M | $7.5M | |
| Operating lease obligations | $19.8M | $23.9M | |
| Other noncurrent liabilities | $2.1M | $1.5M | |
| Long-term debt, net of debt issuance costs | $45.5M | $57.5M | |
| Total liabilities | $288.6M | $263.9M | |
| Redeemable Noncontrolling Interest (See Note 4) | $30.0M | $25.0M | $22.2M |
| Common stock, $0.001 par value; 500,000,000 authorized as of each of June 30, 2026 and 2025; 137,483,028 issued and 136,020,049 outstanding as of June 30, 2026 and 136,903,271 issued and 135,440,292 outstanding as of June 30, 2025. | $137.0K | $137.0K | |
| Treasury stock at cost, 1,462,979 and 1,462,979 shares as of June 30, 2026 and June 30, 2025, respectively | -$7.5M | -$7.5M | |
| Additional paid-in capital | $348.7M | $343.4M | |
| Retained deficit | -$105.8M | -$101.0M | |
| Total InnovAge Holding Corp. | $235.6M | $235.0M | |
| Noncontrolling interests | $3.2M | $2.9M | |
| Total stockholders equity | $238.8M | $237.9M | $277.6M |
| Total liabilities and stockholders equity | $557.4M | $526.9M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock authorized (in shares) | 500.0M shares | 500.0M shares | |
| Common stock issued (in shares) | 137.5M shares | 136.9M shares | |
| Common stock outstanding (in shares) | 136.0M shares | 135.4M shares | |
| Treasury stock at cost (in shares) | 1.5M shares | 1.5M shares |
| Period ending | 2026-06-30 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|
| Cash and cash equivalents | $97.9M | $64.1M | |
| Short-term investments | $43.4M | $41.8M | |
| Restricted cash | $10.0K | $11.0K | |
| Accounts receivable | $42.4M | $36.4M | |
| Prepaid expenses and other | $27.3M | $24.5M | |
| Income tax receivable | $3.3M | $3.3M | |
| Assets held for sale | $0 | $6.0M | |
| Total current assets | $214.3M | $176.1M | |
| Property and equipment, net | $166.1M | $168.0M | |
| Operating lease assets | $21.4M | $26.9M | |
| Deposits and other | $10.3M | $9.9M | |
| Goodwill | $142.0M | $142.0M | $139.9M |
| Other intangible assets, net | $3.2M | $3.9M | |
| Total noncurrent assets | $343.1M | $350.7M | |
| Total assets | $557.4M | $526.9M | |
| Accounts payable and accrued expenses | $115.4M | $76.8M | |
| Reported and estimated claims | $56.9M | $59.0M | |
| Due to Medicaid and Medicare | $18.3M | $14.4M | |
| Current portion of long-term debt | $2.5M | $2.2M | |
| Current portion of finance lease obligations | $6.3M | $5.2M | |
| Current portion of operating lease obligations | $4.6M | $4.7M | |
| Liabilities held for sale | $0 | $2.5M | |
| Total current liabilities | $203.9M | $164.8M | |
| Deferred tax liability, net | $9.1M | $8.8M | |
| Finance lease obligations | $8.3M | $7.5M | |
| Operating lease obligations | $19.8M | $23.9M | |
| Other noncurrent liabilities | $2.1M | $1.5M | |
| Long-term debt, net of debt issuance costs | $45.5M | $57.5M | |
| Total liabilities | $288.6M | $263.9M | |
| Redeemable Noncontrolling Interest (See Note 4) | $30.0M | $25.0M | $22.2M |
| Common stock, $0.001 par value; 500,000,000 authorized as of each of June 30, 2026 and 2025; 137,483,028 issued and 136,020,049 outstanding as of June 30, 2026 and 136,903,271 issued and 135,440,292 outstanding as of June 30, 2025. | $137.0K | $137.0K | |
| Treasury stock at cost, 1,462,979 and 1,462,979 shares as of June 30, 2026 and June 30, 2025, respectively | -$7.5M | -$7.5M | |
| Additional paid-in capital | $348.7M | $343.4M | |
| Retained deficit | -$105.8M | -$101.0M | |
| Total InnovAge Holding Corp. | $235.6M | $235.0M | |
| Noncontrolling interests | $3.2M | $2.9M | |
| Total stockholders equity | $238.8M | $237.9M | $277.6M |
| Total liabilities and stockholders equity | $557.4M | $526.9M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock authorized (in shares) | 500.0M shares | 500.0M shares | |
| Common stock issued (in shares) | 137.5M shares | 136.9M shares | |
| Common stock outstanding (in shares) | 136.0M shares | 135.4M shares | |
| Treasury stock at cost (in shares) | 1.5M shares | 1.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Net loss | -$683.0K | -$35.3M |
| (Gain) loss on disposal of assets | -$418.0K | $508.0K |
| Provision for uncollectible accounts | $0 | $524.0K |
| Depreciation and amortization | $21.1M | $19.5M |
| Operating lease rentals | $6.9M | $6.4M |
| Loss (gain) on cost and equity method investments | $0 | $1.4M |
| Impairments and loss on assets held for sale | $3.2M | $13.6M |
| Amortization of deferred financing costs | $772.0K | $429.0K |
| Stock-based compensation | $7.0M | $7.6M |
| Deferred income taxes | $289.0K | $1.3M |
| Other | $3.1M | $1.7M |
| Accounts receivable | -$6.0M | $11.2M |
| Prepaid expenses and other | -$2.8M | -$4.0M |
| Income tax receivable | $34.0K | $14.0K |
| Deposits and other | -$1.9M | -$6.4M |
| Accounts payable and accrued expenses | $38.4M | $20.4M |
| Reported and estimated claims | -$2.1M | $3.6M |
| Due to Medicaid and Medicare | $3.9M | -$814.0K |
| Operating lease liabilities | -$6.0M | -$8.7M |
| Net cash provided by operating activities | $64.7M | $32.9M |
| Purchases of property and equipment | -$14.3M | -$6.3M |
| Purchases of short-term investments | -$1.7M | -$2.1M |
| Proceeds from sale of short-term investments | $0 | $6.3M |
| Proceeds from dissolution of equity method investments | $0 | $1.3M |
| Acquisition of business | $0 | -$4.8M |
| Proceeds from sale of assets held for sale | $3.7M | $0 |
| Net cash used in investing activities | -$12.3M | -$5.5M |
| Payments for finance lease obligations | -$5.2M | -$6.1M |
| Proceeds from long-term debt | $60.1M | $0 |
| Principal payments on long-term debt | -$71.3M | -$3.8M |
| Payment of debt issuance costs | -$2.0M | $0 |
| Repurchase of equity securities | $0 | -$7.3M |
| Contributions from joint venture partner | $3.2M | $0 |
| Distributions to joint venture partner | -$1.6M | $0 |
| Taxes paid related to net settlements of stock-based compensation awards | -$1.7M | -$1.9M |
| Net cash used in financing activities | -$18.5M | -$19.1M |
| Net change in cash, cash equivalents and restricted cash including cash of $0.08 million reclassified to assets held for sale | $33.8M | $8.2M |
| Less: change in cash and restricted cash reclassified to assets held for sale | -$82.0K | -$1.1M |
| INCREASE IN CASH, CASH EQUIVALENTS & RESTRICTED CASH | $33.8M | $7.2M |
| Interest paid | $4.2M | $4.3M |
| Income taxes paid | $627.0K | $1.0K |
| Property and equipment included in accounts payable | $1.3M | $1.7M |
| Property and equipment purchased under capital leases | $7.0M | $1.5M |
No quarter-by-quarter statement was filed.
Corporate structure
InnovAge Holding Corp. sits at the top of its group. 25 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of InnovAge Holding Corp.
- TCO GROUP HOLDINGS, L.P. Filed SC 13G/A on InnovAge Holding Corp., latest Nov 13, 2024 (2 filings since Feb 11, 2022)
- InnovAge Holding Corp. Denver, Colorado
- ConcertoCare PACE of Bakersfield, LLC Subsidiary · Delaware, United States
- ConcertoHealth PACE of Los Angeles, LLC Subsidiary · Delaware, United States
- InnovAge California PACE - Los Angeles, LLC Subsidiary · Delaware, United States
- InnovAge California PACE - Sacramento, LLC Subsidiary · Delaware, United States
- InnovAge Florida PACE II, LLC Subsidiary · Delaware, United States
- InnovAge Florida PACE, LLC Subsidiary · Delaware, United States
- InnovAge Greater Colorado PACE - Loveland, LLC Subsidiary · Colorado, United States
- InnovAge Investment Holdings, LLC Subsidiary · Delaware, United States
- InnovAge Pennsylvania LIFE, LLC Subsidiary · Pennsylvania, United States
- InnovAge Pharmacy, LLC Subsidiary · Delaware, United States
- InnovAge Virginia PACE - Charlottesville, LLC Subsidiary · Virginia, United States
- InnovAge Virginia PACE - Roanoke Valley, LLC Subsidiary · Virginia, United States
- InnovAge Virginia PACE II, LLC Subsidiary · Virginia, United States
- Innovative Care Management, Inc. Subsidiary · Delaware, United States
- Senior Life at Home II, LLC Subsidiary · Colorado, United States
- Senior Life at Home, LLC Subsidiary · Colorado, United States
- TCO Eastern Holdings, LLC Subsidiary · Delaware, United States
- TCO Intermediate Holdings, Inc. Subsidiary · Delaware, United States
- TCO Western Holdings, LLC Subsidiary · Delaware, United States
- TLC Inland, LLC Subsidiary · Delaware, United States
- Total Community Care, LLC Subsidiary · Colorado, United States
- Total Community Options, Inc. Subsidiary · Colorado, United States
- Total Longterm Care Solutions, LLC Subsidiary · Colorado, United States
- Total Longterm Care, Inc. Subsidiary · Colorado, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What InnovAge Holding Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Finance-lease assets | $14.5M2 Jun 30, 2026 | $13.4M2 Jun 30, 2025 | +8.2% |
| Operating-lease assets (leased space) | $21.4M2 Jun 30, 2026 | $26.9M2 Jun 30, 2025 | −20.4% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $97.9M2 Jun 30, 2026 | $64.1M2 Jun 30, 2025 | +52.6% |
| Marketable securities, current | $43.4M2 Jun 30, 2026 | $41.8M2 Jun 30, 2025 | +4.0% |
| Long-term investments | $010 Jun 30, 2025 | $2.6M10 Jun 30, 2024 | −100.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $142.0M2 Jun 30, 2026 | $142.0M2 Jun 30, 2025 | 0% |
| Intangible assets, net (excluding goodwill) | $3.2M2 Jun 30, 2026 | $3.9M2 Jun 30, 2025 | −17.0% |
| Indefinite-lived intangibles (excluding goodwill) | $2.0M2 Jun 30, 2026 | $2.0M2 Jun 30, 2025 | 0% |
| Finite-lived intangibles, gross | $6.6M2 Jun 30, 2026 | $6.6M2 Jun 30, 2025 | 0% |
| Accumulated amortization | $5.4M2 Jun 30, 2026 | $4.7M2 Jun 30, 2025 | +14.0% |
Properties, in its own words
As of June 30, 2026, we operated an aggregate of 20 PACE centers, of which ten were owned and ten were leased, representing approximately 410,000 and 240,000 gross square feet, respectively. Our centers are located in 14 markets and six states.
Our principal executive offices are located in Denver, Colorado, where we own facilities totaling approximately 290,000 square feet across the state. We occupy a 69,000 square foot facility for administration, sales and marketing, technology and development and professional services in Denver, Colorado. We also own and lease properties for operational PACE centers in Denver, Colorado; Loveland, Colorado; Pueblo, Colorado; Albuquerque, New Mexico; Los Angeles, California; Sacramento, California; San Bernardino, California; Philadelphia, Pennsylvania; Charlottesville, Virginia; Newport News, Virginia; Richmond, Virginia; Roanoke, Virginia; Orlando, Florida; and Tampa, Florida. We also lease properties for PACE centers that are not operational. We do not have any PACE centers or properties located outside of the United States.
The rest of Item 2
Our leases have an average original term of ten years, and generally provide for renewal or extension options. Our lease obligations often include annual fixed rent escalators ranging between 2.0% and 3.0%. Generally, our leases are “modified gross” leases, which require us to pay the cost of insurance, taxes, maintenance and utilities, but not for costs related to the structure of the building. We generally cannot cancel these leases at our option.
We believe that our facilities and centers are adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional space will be available to accommodate any such expansion of our operations.
Item 2 of the 10-K filed Sep 9, 2026.5
Leadership
Who has led InnovAge Holding Corp., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
- Chief executive officerPatrick T. Blair Dec 5, 2022 to now14
- Chief executive officerMaureen Hewitt Mar 3, 2021 to Mar 12, 202115
- PresidentJennifer Browne Jun 8, 2026 to now16
- PresidentMichael Anthony Scarbrough Nov 4, 2024 to Jun 8, 202617
- PresidentMaureen Hewitt Mar 3, 2021 to Mar 12, 202115
- PresidentPatrick T. Blair Dec 3, 2021 to Sep 4, 202418
- Chief financial officerBarbara Gutierrez Mar 3, 2021 to Mar 15, 202119
- Chief operating officerJennifer Browne Jun 8, 2026 to now16
- Chief operating officerMichael Anthony Scarbrough Nov 4, 2024 to Jun 8, 202617
- Chief operating officerMaria Lozzano Mar 3, 2021 to Mar 3, 202120
Board members and other officers (19)
- Chief Medical OfficerPaul Taheri Aug 17, 2026 to now21
- Chief Administrative OfficerMeredith Delk Oct 9, 2025 to now22
- CHIEF OPERATIONS OFFICERChristine Bent Mar 23, 2023 to Jun 7, 202423
- CHIEF MEDICAL OFFICERRichard Feifer Aug 17, 2022 to Aug 19, 202424
- CHIEF MEDICAL OFFICERMelissa Welch Mar 3, 2021 to Mar 3, 202125
- CHIEF SALES AND MKTG. OFFICERRobin Doerr Mar 3, 2021 to Mar 16, 202126
- Board memberPatricia Fontneau Apr 3, 2023 to now27
- Board memberTeresa Sparks Aug 14, 2023 to now28
- Board memberJames G. Carlson Jul 5, 2022 to now29
- Board memberAndrew J. Cavanna Mar 3, 2021 to Mar 3, 202130
- Board memberCaroline Dechert Mar 3, 2021 to Mar 3, 202131
- Board memberEdward Moore Kennedy Jr. Mar 3, 2021 to now32
- Board memberMarilyn B. Tavenner Mar 3, 2021 to now33
- Board memberMaureen Hewitt Mar 3, 2021 to Mar 12, 202115
- Board memberPavithra Mahesh Mar 3, 2021 to now34
- Board memberRichard C. Zoretic Mar 3, 2021 to now35
- Board memberSean Traynor Mar 3, 2021 to now36
- Board memberThomas Scully Mar 3, 2021 to Sep 19, 202237
- General counselNicole Damato Sep 24, 2021 to now38
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- ConcertoCare PACE of Bakersfield, LLC Delaware4
- ConcertoHealth PACE of Los Angeles, LLC Delaware4
- InnovAge California PACE - Los Angeles, LLC Delaware4
- InnovAge California PACE - Sacramento, LLC Delaware4
- InnovAge Florida PACE II, LLC Delaware4
- InnovAge Florida PACE, LLC Delaware4
- InnovAge Greater Colorado PACE - Loveland, LLC Colorado4
- InnovAge Holding Corp. Delaware4
- InnovAge Investment Holdings, LLC Delaware4
- InnovAge Pennsylvania LIFE, LLC Pennsylvania4
- InnovAge Pharmacy, LLC Delaware4
- InnovAge Virginia PACE - Charlottesville, LLC Virginia4
- InnovAge Virginia PACE - Roanoke Valley, LLC Virginia4
- InnovAge Virginia PACE II, LLC Virginia4
- Innovative Care Management, Inc. Delaware4
- Senior Life at Home II, LLC Colorado4
- Senior Life at Home, LLC Colorado4
- TCO Eastern Holdings, LLC Delaware4
- TCO Intermediate Holdings, Inc. Delaware4
- TCO Western Holdings, LLC Delaware4
- TLC Inland, LLC Delaware4
- Total Community Care, LLC Colorado4
- Total Community Options, Inc. Colorado4
- Total Longterm Care Solutions, LLC Colorado4
All 25 listed subsidiaries
- Total Longterm Care, Inc. Colorado4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- TCO GROUP HOLDINGS, INC.Dec 17, 2020 to Jan 20, 20213
Timeline
- Sep 24, 20268-K Other events39
- Sep 8, 20268-K Results of operations40
- May 18, 20268-K Regulation FD disclosure41
- May 12, 20268-K Executive or director change; Regulation FD disclosure42
- May 5, 20268-K Results of operations43
- Mar 17, 20268-K Regulation FD disclosure44
- Feb 3, 20268-K Results of operations45
- Jan 29, 20268-K Executive or director change; Regulation FD disclosure46
- Jan 12, 20268-K Regulation FD disclosure47
- Dec 4, 20258-K Shareholder vote48
- Nov 4, 20258-K Results of operations49
- Oct 23, 20258-K Executive or director change50
- Dec 5, 2022New chief executive Patrick T. Blair becomes CEO14
- Mar 3, 2021New chief executive Maureen Hewitt becomes CEO15
Calendar
Coming up
- Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.06 a share, on Nov 4, 2025.51
When it reported results
- Sep 8, 2026Reported quarterly or annual results40
- May 5, 2026Reported quarterly or annual results43
- Feb 3, 2026Reported quarterly or annual results45
- Nov 4, 2025Reported quarterly or annual results49
- Sep 9, 2025Reported quarterly or annual results52
- May 6, 2025Reported quarterly or annual results53
- Feb 4, 2025Reported quarterly or annual results54
- Nov 5, 2024Reported quarterly or annual results55
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
212 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 52 major events, 113 insider forms, 2 large holders, 24 other. The latest 20:
- Sep 29, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 25, 2026144 EDGAR
- Sep 24, 20268-K EDGAR
- Sep 24, 2026424B4 EDGAR
- Sep 22, 2026424B7 EDGAR
- Sep 9, 202610-K EDGAR
- Sep 8, 20268-K EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Aug 17, 20263 EDGAR
- Aug 4, 2026EFFECT EDGAR
- Jul 31, 2026S-3 EDGAR
- Jul 27, 20264 EDGAR
- Jul 23, 20264 EDGAR
- Jul 23, 20264 EDGAR
- Jul 23, 20264 EDGAR
The 212 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
29 open-market trades by officers, directors and large owners since October 2021: 12 buys and 17 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | DAMATO NICOLECHIEF LEGAL OFFICER | Sale | 23,814 | $8.70 | $207.2K | Form 4 |
| Sep 24, 2026 | TCO GROUP HOLDINGS, L.P.10% owner | Sale | 10,000,000 | $9.25 | $92.5M | Form 4 |
| Sep 24, 2026 | IGNITE AGGREGATOR LP10% owner | Sale | 10,000,000 | $9.25 | $92.5M | Form 4 |
| Sep 24, 2026 | WCAS CO-INVEST ASSOCIATES LLC10% owner | Sale | 10,000,000 | Form 4 | ||
| Nov 14, 2025 | SCARBROUGH MICHAEL ANTHONYPresident and COO | Sale | 33,000 | $4.90 | $161.7K | Form 4 |
| May 30, 2025 | ZORETIC RICHARD CDirector | Buy | 8,450 | $4.08 | $34.5K | Form 4 |
| May 29, 2025 | ZORETIC RICHARD CDirector | Buy | 14,265 | $4.04 | $57.6K | Form 4 |
| May 28, 2025 | ZORETIC RICHARD CDirector | Buy | 20,000 | $4.06 | $81.2K | Form 4 |
| May 23, 2025 | ZORETIC RICHARD CDirector | Buy | 1,198 | $3.93 | $4.7K | Form 4 |
| May 22, 2025 | ZORETIC RICHARD CDirector | Buy | 700 | $4.09 | $2.9K | Form 4 |
| May 21, 2025 | ZORETIC RICHARD CDirector | Buy | 1,147 | $4.13 | $4.7K | Form 4 |
| May 20, 2025 | ZORETIC RICHARD CDirector | Buy | 807 | $4.20 | $3.4K | Form 4 |
| May 16, 2025 | ZORETIC RICHARD CDirector | Buy | 2,086 | $4.28 | $8.9K | Form 4 |
| May 13, 2025 | SCARBROUGH MICHAEL ANTHONYPresident and COO | Buy | 10,000 | $3.89 | $38.9K | Form 4 |
| May 12, 2025 | SCARBROUGH MICHAEL ANTHONYPresident and COO | Buy | 13,000 | $3.73 | $48.5K | Form 4 |
| May 9, 2025 | SCARBROUGH MICHAEL ANTHONYPresident and COO | Buy | 10,000 | $3.55 | $35.5K | Form 4 |
| Nov 6, 2024 | DAMATO NICOLECHIEF LEGAL OFFICER | Sale | 1,660 | $6.54 | $10.9K | Form 4 |
| Sep 17, 2024 | DAMATO NICOLECHIEF LEGAL OFFICER | Sale | 7,521 | $6.00 | $45.1K | Form 4 |
| Sep 16, 2024 | DAMATO NICOLECHIEF LEGAL OFFICER | Sale | 4,372 | $5.95 | $26.0K | Form 4 |
| Jul 18, 2023 | DAMATO NICOLECHIEF LEGAL OFFICER | Sale | 4,000 | $7.12 | $28.5K | Form 4 |
All 29 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- TCO GROUP HOLDINGS, L.P.SC 13G/A, 2 filings Feb 11, 2022 to Nov 13, 202456
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Patrick BlairChief Executive Officer | 54 | $770.0K | $1.5M57 |
| 2025 | Michael ScarbroughPresident and Chief Operating Officer | $317.6K | $1.5M57 | |
| 2025 | Nicole D’AmatoChief Legal Officer and Corporate Secretary | 46 | $457.0K | $766.1K57 |
| 2024 | Patrick BlairChief Executive Officer | 54 | $826.5K | $4.9M57 |
| 2024 | Nicole D’AmatoChief Legal Officer and Corporate Secretary | 46 | $468.9K | $1.6M57 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How InnovAge Holding Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARInnovAge Holding Corp.1
- CIK0001834376
- Employer ID (EIN)81-07108195
- Filer statusAccelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsJune 301
- Industry code (SIC)8000 Services-Health Services1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address8950 E. Lowry Boulevard, Denver, CO 802301
- Phone(303) 869-46641
- Shares outstanding136,451,425 shares as of Sep 1, 20265
- Public float$111.4M as of Dec 31, 20255
- AuditorDELOITTE & TOUCHE LLP, Denver, CO PCAOB ID 34; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceDec 17, 20201
- Filings261 in all: 4 (104), 8-K (56), 3 (31), 10-Q (16), 10-K (6), CORRESP (5), DEF 14A (5), DEFA14A (5)1
All 27 form types
144 (4), UPLOAD (4), ARS (3), S-1/A (3), 424B4 (2), DRS (2), EFFECT (2), PRE 14A (2), 10-K/A (1), 424B7 (1), 8-A12B (1), CERT (1), DRS/A (1), DRSLTR (1), S-1 (1), S-3 (1), S-8 (1), SC 13G (1), SC 13G/A (1)
- Latest filingsAnnual report (10-K) Sep 9, 2026
Quarterly report (10-Q) May 8, 2026
Proxy statement (DEF 14A) Oct 23, 2025
Latest 8-K (8-K) Sep 24, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.001 par value | INNV | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Sep 9, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks InnovAge Holding Corp. names in Item 1A of its 10-K filed Sep 9, 2026: 43 risks under these headings, as written.5
- •Our growth strategy may not prove viable.
- •Our growth strategy depends upon our ability to identify and complete acquisitions, joint ventures and other strategic partnerships.
- Risks Related to Our Business
- Our growth strategy may not prove viable and we may fail to realize expected results therefrom fully or at all.
- Our growth strategy is partially dependent upon our ability to identify and successfully complete acquisitions, joint ventures and other strategic partnerships.
- If we are unable to attract new participants and retain existing participants, our revenue growth will be adversely affected.
- Our overall business results have been, and we expect will continue to be, impacted by ongoing macroeconomic, geopolitical and industry-related challenges, including labor shortages, labor competition, inflation, and supply chain disruption as a result of tariffs and trade disputes.
- Under our PACE contracts, we assume all of the risk that the cost of providing services will exceed our compensation.
- We have experienced, and expect to continue experiencing, increased costs and expenditures in the future.
- Our dependence on Medicare and Medicaid exposes us to risks from government funding reductions, legislative changes including the Reconciliation Act, and federal and state budgetary pressures.
- Reductions in PACE reimbursement rates, changes in risk adjustment methodologies, or changes in the rules governing PACE programs could have a material adverse effect on our financial condition and results of operations.
- We have faced and continue to face inspections, reviews, audits and investigations under federal and state government programs and contracts. These audits have required and may in the future require corrective actions and have resulted
The other 32 risks
- in adverse findings that have negatively affected and continue to affect our business, including our results of operations, liquidity, financial condition and reputation.
- We are subject to legal proceedings, enforcement actions and litigation, malpractice and privacy disputes, which are costly to defend and could materially harm our business and results of operations.
- Our records and other information and materials submitted to government payors may contain inaccurate or unsupportable information applicable to participants’ risk scores, which could cause us to overstate or understate our revenue and subject us to repayment obligations or penalties.
- We depend on our senior management team and other key employees, and the loss of one or more of these employees or an inability to attract and retain other highly skilled employees could harm our business.
- If certain of our suppliers do not meet our needs, if we are not reimbursed or adequately reimbursed for medical products we purchase or if we are unable to effectively access new technology or medical products, our ability to effectively provide the services we offer could be negatively impacted.
- Our acquisition of certain pharmacy assets and the management of our own pharmacy services exposes us to novel risks.
- If we fail to manage our operations effectively, we may be unable to execute our business plan, maintain effective levels of service and participant satisfaction or adequately address competitive challenges.
- The healthcare industry is highly competitive and, if we are not able to compete effectively, our business could be harmed.
- Our presence is currently limited to six states, with a significant percentage of our operations in the States of California and Colorado. As a result, we are particularly susceptible to regulatory issues and reduction in budget appropriations for our services or any other adverse developments in that state.
- Security breaches, loss of data and other disruptions, including disruptions in our disaster recovery systems, have in the past and could in the future compromise sensitive information related to our business or our participants, or prevent us from accessing critical information and expose us to liability, and could adversely affect our business and our reputation.
- Our use of AI and machine learning technologies, and the use of such technologies by our third-party vendors, may expose us to operational, competitive, regulatory, legal and reputational risks that could adversely affect our business, financial condition and results of operations.
- A failure to accurately estimate incurred but not reported medical expenses could adversely affect our results of operations.
- We lease half of our centers and may experience risks relating to lease termination, lease expense escalators, lease extensions and special charges.
- A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide, as well as weather and other factors, have affected, and could in the future adversely affect our business.
- Risks Related to Regulation
- We operate in a highly regulated environment at the federal and state level, and failure to adhere to the laws and regulations that apply to our business could result in regulatory scrutiny, which have had, and could in the future have, a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price.
- Federal and state manuals, policies, and other guidance may affect our operations.
- If we are unable to effectively adapt to changes in the healthcare industry, including changes to laws and regulations regarding or affecting U.S. healthcare reform, our business could be harmed.
- Laws regulating the corporate practice of medicine could restrict the manner in which we are permitted to conduct our business, and the failure to comply with such laws could subject us to penalties or require a restructuring of our business.
- Our use, disclosure, and other processing of PHI/PII is subject to HIPAA, CCPA as amended by the CPRA and other federal and state privacy and security regulations, and our failure to comply with those laws and regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our participant base and revenue.
- Risks Related to Our Indebtedness and Liquidity
- Our existing indebtedness could adversely affect our business.
- Our failure to raise additional capital or generate cash flows necessary to expand our operations and invest in participant services in the future could reduce our ability to compete successfully and harm our results of operations.
- Risks Related to Our Common Stock
- Our operating results have fluctuated and may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause such results to fall below any guidance, targets or goals we provide.
- Our stock price is volatile.
- Our Principal Shareholders control us, and their interests may conflict with our interests and those of our other shareholders.
- We are a “controlled company” within the meaning of the rules of Nasdaq and, as a result, we qualify for, and intend to continue relying on, exemptions from certain corporate governance requirements. Therefore, shareholders do not have the same protections as those afforded to shareholders of companies that are subject to such governance requirements.
- We qualify as a “smaller reporting company” and we have elected to comply with reduced public company reporting requirements, which could make our common stock less attractive to investors.
- The requirements of being a public company may strain our resources and distract our management, which could make it difficult to manage our business, particularly since we no longer qualify as an “emerging growth company.”
- Provisions of our corporate governance documents could make an acquisition of us more difficult and may prevent attempts by our shareholders to replace or remove our current management, even if beneficial to our shareholders.
- Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our shareholders and the federal district courts of the United States as the exclusive forum for litigation arising under the Securities Act, which could limit our shareholders’ ability to obtain a favorable judicial forum for disputes with us.
- A significant portion of our total outstanding shares may be sold into the market. This could cause the market price of our common stock to drop significantly, even if our business is doing well.
- Our Board has in the past approved, and may in the future approve, a share repurchase program that would subject us to certain risks, which could be exacerbated because our stock is thinly traded.
- Future offerings of debt or equity securities by us may materially adversely affect the market price of our common stock.
Legal proceedings
From time to time, we may be involved in various legal proceedings and be subject to claims.
For information regarding our material pending legal proceedings, refer to Note 9 “Commitments and Contingencies” to the consolidated financial statements included in this Annual Report for more information.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARJennifer Browne, President
- 17
- 18SEC EDGARPatrick T. Blair, President
- 19
- 20
- 21SEC EDGARPaul Taheri, Chief Medical Officer
- 22
- 23
- 24
- 25SEC EDGARMelissa Welch, CHIEF MEDICAL OFFICER
- 26
- 27SEC EDGARPatricia Fontneau, Board member
- 28SEC EDGARTeresa Sparks, Board member
- 29SEC EDGARJames G. Carlson, Board member
- 30SEC EDGARAndrew J. Cavanna, Board member
- 31SEC EDGARCaroline Dechert, Board member
- 32
- 33SEC EDGARMarilyn B. Tavenner, Board member
- 34SEC EDGARPavithra Mahesh, Board member
- 35SEC EDGARRichard C. Zoretic, Board member
- 36SEC EDGARSean Traynor, Board member
- 37SEC EDGARThomas Scully, Board member
- 38SEC EDGARNicole Damato, General counsel
- 39SEC EDGAROther events
- 40SEC EDGARResults of operations
- 41SEC EDGARRegulation FD disclosure
- 42
- 43SEC EDGARResults of operations
- 44SEC EDGARRegulation FD disclosure
- 45SEC EDGARResults of operations
- 46
- 47SEC EDGARRegulation FD disclosure
- 48SEC EDGARShareholder vote
- 49SEC EDGARResults of operations
- 50SEC EDGARExecutive or director change
- 51NasdaqNasdaq calendar
- 52
- 53
- 54
- 55
- 56
- 57